182 related articles for article (PubMed ID: 34006333)
21. Beyond Standard Practice in Liquid Biopsy: Selective Venous Sampling.
Damascelli B; Tichà V; Repetti E; Dorji T
J Vasc Interv Radiol; 2021 May; 32(5):668-671. PubMed ID: 33621662
[TBL] [Abstract][Full Text] [Related]
22. Implementing circulating tumor DNA analysis in a clinical laboratory: A user manual.
Koessler T; Addeo A; Nouspikel T
Adv Clin Chem; 2019; 89():131-188. PubMed ID: 30797468
[TBL] [Abstract][Full Text] [Related]
23. Meltos: multi-sample tumor phylogeny reconstruction for structural variants.
Ricketts C; Seidman D; Popic V; Hormozdiari F; Batzoglou S; Hajirasouliha I
Bioinformatics; 2020 Feb; 36(4):1082-1090. PubMed ID: 31584621
[TBL] [Abstract][Full Text] [Related]
24. Multiplex structural variant detection by whole-genome mapping and nanopore sequencing.
Uppuluri L; Wang Y; Young E; Wong JS; Abid HZ; Xiao M
Sci Rep; 2022 Apr; 12(1):6512. PubMed ID: 35444207
[TBL] [Abstract][Full Text] [Related]
25. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
[TBL] [Abstract][Full Text] [Related]
26. Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients.
Martignano F; Munagala U; Crucitta S; Mingrino A; Semeraro R; Del Re M; Petrini I; Magi A; Conticello SG
Mol Cancer; 2021 Feb; 20(1):32. PubMed ID: 33579306
[TBL] [Abstract][Full Text] [Related]
27. Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing.
Katsman E; Orlanski S; Martignano F; Fox-Fisher I; Shemer R; Dor Y; Zick A; Eden A; Petrini I; Conticello SG; Berman BP
Genome Biol; 2022 Jul; 23(1):158. PubMed ID: 35841107
[TBL] [Abstract][Full Text] [Related]
28. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection.
Bartels S; Persing S; Hasemeier B; Schipper E; Kreipe H; Lehmann U
J Mol Diagn; 2017 Sep; 19(5):722-732. PubMed ID: 28723342
[TBL] [Abstract][Full Text] [Related]
29. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.
Postel M; Roosen A; Laurent-Puig P; Taly V; Wang-Renault SF
Expert Rev Mol Diagn; 2018 Jan; 18(1):7-17. PubMed ID: 29115895
[TBL] [Abstract][Full Text] [Related]
30. SVExpress: identifying gene features altered recurrently in expression with nearby structural variant breakpoints.
Zhang Y; Chen F; Creighton CJ
BMC Bioinformatics; 2021 Mar; 22(1):135. PubMed ID: 33743584
[TBL] [Abstract][Full Text] [Related]
31. Computational Analysis of DNA and RNA Sequencing Data Obtained from Liquid Biopsies.
Marass F; Castro-Giner F; Szczerba BM; Jahn K; Kuipers J; Aceto N; Beerenwinkel N
Recent Results Cancer Res; 2020; 215():347-368. PubMed ID: 31605238
[TBL] [Abstract][Full Text] [Related]
32. A Pipeline for ctDNA Detection Following Primary Tumor Profiling Using a Cancer-Related Gene Sequencing Panel.
Nishizuka SS; Sato KA; Hachiya T
Methods Mol Biol; 2019; 1908():229-241. PubMed ID: 30649732
[TBL] [Abstract][Full Text] [Related]
33. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
34. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
Luo H; Wei W; Ye Z; Zheng J; Xu RH
Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
[TBL] [Abstract][Full Text] [Related]
35. Bioinformatics Analysis for Cell-Free Tumor DNA Sequencing Data.
Chen S; Liu M; Zhou Y
Methods Mol Biol; 2018; 1754():67-95. PubMed ID: 29536438
[TBL] [Abstract][Full Text] [Related]
36. Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics.
van Ginkel JH; van den Broek DA; van Kuik J; Linders D; de Weger R; Willems SM; Huibers MMH
Cancer Med; 2017 Oct; 6(10):2297-2307. PubMed ID: 28940814
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
[TBL] [Abstract][Full Text] [Related]
38. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
Barlebo Ahlborn L; Østrup O
APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
[TBL] [Abstract][Full Text] [Related]
39. Analysis of Circulating Tumor DNA.
Mithraprabhu S; Spencer A
Methods Mol Biol; 2018; 1792():129-145. PubMed ID: 29797256
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Monitoring of Circulating DNA Mutations in Metastatic Cancer with Personalized Digital PCR.
Wood-Bouwens CM; Haslem D; Moulton B; Almeda AF; Lee H; Heestand GM; Nadauld LD; Ji HP
J Mol Diagn; 2020 Feb; 22(2):247-261. PubMed ID: 31837432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
